Skip to content
  • Tuesday, 30 June 2026
  • 7:24 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • FDA Approves Langlara, an Interchangeable Biosimilar for Diabetes Management, Expanding Patient Access and Treatment Options
Pharmaceutical R&D

FDA Approves Langlara, an Interchangeable Biosimilar for Diabetes Management, Expanding Patient Access and Treatment Options

Teuku Ryan May 6, 2026 0

Sunshine Lake Pharma, Lannett Company, and its wholly owned subsidiary Lanexa Biologics have achieved a significant milestone in diabetes care…

Read More
Pharmaceutical R&D

Teva Pharmaceutical Secures FDA Approval for Ponlimsi Biosimilar to Prolia, Advances Xolair Biosimilar Applications in US and EU

Teuku Ryan Apr 1, 2026 0

Teva Pharmaceutical has announced a significant milestone in its biosimilar portfolio with the U.S. Food and Drug Administration (FDA) granting…

Read More
Python Blood Reveals Novel Appetite Suppressant, Offering New Hope for Weight Loss and Metabolic Health TherapiesNovo Nordisk Secures FDA Approval for Awiqli, a Once-Weekly Basal Insulin for Adults with Type 2 DiabetesUnderwater compressed air effectively removes coral species invasive to BrazilRethinking Classical Physics as Researchers Bridge the Gap Between Newton’s Third Law and Non-Reciprocal Collective Systems
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveHigh-Dimensional Topological Structures Discovered in Entangled Photons Offer New Framework for Quantum Information StabilityWater-in-Diesel Emulsion Technology Offers Significant Emissions Reduction Potential Without Engine Modification
Glioblastoma Research Reveals Skull Erosion and Immune System Reprogramming Reshaping Treatment StrategiesPioneering Sequencing by Synthesis: David Klenerman Reflects on a Decade of Innovation and the Future of BiotechDiabetes to MASH: the specimens behind GLP-1’s widening rosterSeven Pharma Companies Selected for FDA PreCheck Pilot Program to Bolster U.S. Drug Supply Chain
YOU MAY HAVE MISSED
Stem Cell & Regenerative Medicine
Glioblastoma Research Reveals Skull Erosion and Immune System Reprogramming Reshaping Treatment Strategies
Dwi Wanna Jun 30, 2026
Biotech & Genetic Research
Pioneering Sequencing by Synthesis: David Klenerman Reflects on a Decade of Innovation and the Future of Biotech
Jia Lissa Jun 30, 2026
Laboratory Automation & Robotics
Diabetes to MASH: the specimens behind GLP-1’s widening roster
Lana Keisha Jun 30, 2026
Pharmaceutical R&D
Seven Pharma Companies Selected for FDA PreCheck Pilot Program to Bolster U.S. Drug Supply Chain
Teuku Ryan Jun 30, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ